Clinical Trial Update: A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety, tolerability and preliminary efficacy of NGI226 microparticles in Achilles tendinopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achilles Tendinopathy

Drugs mentioned

• NGI226 microparticles (NGI226)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Achilles Tendinopathy | Phase 2 | Status: COMPLETED